跳转到内容

依诺妥珠单抗

维基百科,自由的百科全书
依诺妥珠单抗
单克隆抗体
种类?
目標B7-H3
臨床資料
其他名稱MGA271
ATC碼
  • 未分配
识别信息
CAS号1353485-38-7
ChemSpider
  • none
UNII
KEGG
化学信息
化学式C6474H9990N1726O2030S42
摩尔质量145,829.71 g·mol−1

依诺妥珠单抗INN:Enoblituzumab;开发代号:MGA271)是一种单克隆抗体,设计用于治疗癌症。[1]该药物是一种人源化IgG1κ单克隆抗体,可识别人类B7-H3(免疫调节剂B7家族的成员)。[2]

该药物由MacroGenics公司开发。[3]

参考资料

[编辑]
  1. ^ Statement On A Nonproprietary Name Adopted By The USAN Council - Enoblituzumab, American Medical Association.
  2. ^ Aggarwal, Charu; Prawira, Amy; Antonia, Scott; Rahma, Osama; Tolcher, Anthony; Cohen, Roger B.; Lou, Yanyan; Hauke, Ralph; Vogelzang, Nicholas; P Zandberg, Dan; Kalebasty, Arash Rezazadeh. Dual checkpoint targeting of B7-H3 and PD-1 with enoblituzumab and pembrolizumab in advanced solid tumors: interim results from a multicenter phase I/II trial. Journal for Immunotherapy of Cancer. 2022-04, 10 (4) [2024-03-12]. ISSN 2051-1426. PMC 9006844可免费查阅. PMID 35414591. doi:10.1136/jitc-2021-004424. (原始内容存档于2024-06-16). 
  3. ^ Enoblituzumab (anti-B7-H3) – MacroGenics. macrogenics.com. [2024-03-12]. (原始内容存档于2024-03-12). 
pFad - Phonifier reborn

Pfad - The Proxy pFad of © 2024 Garber Painting. All rights reserved.

Note: This service is not intended for secure transactions such as banking, social media, email, or purchasing. Use at your own risk. We assume no liability whatsoever for broken pages.


Alternative Proxies:

Alternative Proxy

pFad Proxy

pFad v3 Proxy

pFad v4 Proxy